Modalert is a wakefulness-promoting drug that is used to treat excessive sleepiness caused by disorders like Narcolepsy, Obstructive Sleep Apnea, and Chronic Shift Work Sleep Disorder. It is also a powerful cognitive enhancer.
MOD's wake-promoting effects have been attributed to its modulation of the cholinergic system in brain areas involved in arousal and cognitive functions.
Modafinil Enhances Attention
MOD (Modafinil) and its enantiomer R-MOD are approved medications for narcolepsy but are also used off-label as cognitive enhancers. A series of studies have found that MOD improves performance on cognitive tasks in healthy subjects and those with sleep disorders, and is well-tolerated with few side effects.
Compared to placebo, Modafinil significantly reduced the number of lapses on a Psychomotor Vigilance Test in patients with narcolepsy and improved their response time. In another study, sleep-deprived individuals who took 200 mg of Modafinil per day were able to perform at the same level as when they were fully rested.
In this double-blind, within-participant study, participants were administered either modafinil or a placebo 1 hour after awakening for 23 days during simulated shift work. Linear mixed models demonstrated a main effect of treatment, as well as drug abstinence week-by-time-of-day interaction on polysomnographic sleep measurements and multiple sleep latency tests, subjective measures of wakefulness, and mood.
Modafinil Enhances Memory
Modalert 200 Tablet is used to treat narcolepsy and has also been tested as a cognitive enhancer. Studies suggest it can improve memory, increase vigilance and concentration, and improve learning ability. However, it is important to know the possible side effects of this drug before using it.
In one double-blind study, participants completed cognitive tasks under placebo or 200 mg of modafinil. Each participant was grouped, per task, as high (HP) or low performance (LP). Modafinil enhanced performance in HPs, but not in LPs.
A separate study found that MOD increases the firing of cholinergic neurons in the pedunculopontine nucleus. This finding suggests that MOD increases the coupling of cholinergic neurons in this brain area to increase vigilance and attention. This modulation by cholinergic neurotransmitters is a novel mechanism of action for this wake-promoting agent. It also explains why it is less likely to have the abuse potential of amphetamine-like drugs like methylphenidate.
Modafinil Enhances Focus
Modalert is a wakefulness-promoting agent and has been used, off-label, as a cognitive enhancer by some people. However, several issues need to be considered when using Modalert as a cognitive enhancer.
Several studies have shown that Modalert improves performance after sleep deprivation. One study found that modafinil improved digit span, visual pattern recognition memory, and spatial planning skills in people who had been sleep-deprived for two days. It also reduced the latency of three tests (a decision-making task, a stop-signal reaction time, and rapid visual information processing).
Another study found that modafinil increased alertness in people with shift work sleep disorder (SWSD) who were given 400 mg of modafinil or placebo for 9 weeks. This study found that modafinil was associated with improvements in the standardized tests of sleepiness used to measure narcolepsy and shift work sleep disorder, as well as in the self-rating of sleepiness (ESS). These results suggest that modafinil might be an effective treatment for SWSD with a favorable safety profile.
Modafinil Enhances Cognitive Function
Originally developed to treat narcolepsy (excessive sleeping), the drug modafinil appears to enhance certain cognitive functions according to a new study published in Neuropsychopharmacology. Participants who met inclusion criteria for this randomized placebo-controlled trial were assigned to receive modafinil or placebo, administered every morning upon awakening. Neurocognitive testing was conducted at weekly in-person visits. Sleep quality was measured using the Pittsburgh Sleep Quality Index and daytime sleepiness was assessed with the Epworth sleepiness scale.
The primary domain of interest for this study was cognition, with outcomes measuring processing speed, verbal learning, and spatial working memory. Findings for each of these domains showed a marginally significant treatment group by time interactions, indicating a cognitive advantage in the modafinil group.
Although these results are promising, it is important to note that the small sample size of this study may limit the generalizability of these findings. Additionally, participants were taking mood stabilizers alongside modafinil during the study, which may have influenced the results.
Share this page with your family and friends.